Q: 34 year old female is admitted to the ICU with acute chest pain, syncope, and shortness of breath after hearing the news of her son's car accident, and is diagnosed with stress cardiomyopathy (takotsubo cardiomyopathy) with cardiogenic shock. What are the two main determinants a clinician needs to make?
Answer:
The management of stress cardiomyopathy highly depends on whether there is:
- LVOT obstruction is present, or
- no LVOT obstruction is present
Volume depletion and vasodilator therapy need to be avoided in patients with LVOT obstruction, in contrast to the standard of other cardiogenic shock syndromes. Euvolumeia is preferred with a fine line to avoid pulmonary edema. Patients who develop LVOT obstruction are at higher risk of developing shock. LVOT obstruction can be accompanied by systolic anterior motion (SAM) of the mitral valve and mitral regurgitation, similar to that seen in hypertrophic cardiomyopathy. Inotropic agents should be avoided if SAM or severe LVOT obstruction is present.
A quick clinical bedside tip in management of stress cardiomyopathy with LVOT obstruction when shock is profound is to increase preload with leg elevation and fluid resuscitation, again keeping a close eye on pulmonary edema. Phenylephrine, as a pure alpha-adrenergic agonist (or vasopressin), increases afterload and may help decrease the gradient, thereby improving hemodynamics, though the risk of coronary spasm is inherent. A beta blocker should be added judiciously to reduce inotropy. In such a shock situation, IABP needs to be inserted despite some risk of afterload reduction from IABP.
For reasons not fully understood, younger patients are more prone to develop shock, probably a manifestation of high catecholamine effect.
#hemodynamics
References:
1. Vila-Sanjuán S, Nuñez-Gil IJ, Vedia O, Corbi-Pascual M, Salamanca J, Martinez-Selles M, Blanco E, Almendro-Delia M, Pérez-Castellanos A, Martin-Garcia AC, Tomasino M, Vazirani R, Fernández-Cordón C, Duran Cambra A, Becerra-Muñoz VM, Guillén M, Reyes JA, Uribarri A. Left ventricular outflow tract obstruction in Takotsubo syndrome with cardiogenic shock: prognosis and treatment. Heart. 2024 Nov 19;110(23):1381-1388. doi: 10.1136/heartjnl-2024-324205. PMID: 39209437.
2. Ozaki K, Okubo T, Tanaka K, Hosaka Y, Tsuchida K, Takahashi K, Oda H, Minamino T. Manifestation of Latent Left Ventricular Outflow Tract Obstruction in the Acute Phase of Takotsubo Cardiomyopathy. Intern Med. 2016;55(23):3413-3420. doi: 10.2169/internalmedicine.55.7119. Epub 2016 Dec 1. PMID: 27904102; PMCID: PMC5216136.
3. Kawaji T, Shiomi H, Morimoto T, Tazaki J, Imai M, Saito N, Makiyama T, Shizuta S, Ono K, Kimura T. Clinical impact of left ventricular outflow tract obstruction in takotsubo cardiomyopathy. Circ J. 2015;79(4):839-46. doi: 10.1253/circj.CJ-14-1148. Epub 2015 Jan 28. PMID: 25739572.